SCIASCIA THOMAS

SEC source: 0001193125-26-061394 · ownership.xml · derivative · entry 1

SCIASCIA THOMAS · CIK 0001229946 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 85,000

Underlying: Common Stock · 85,000 shares

Expires 2036-02-18

F1 · derivative.exercise_date: This option was granted on February 19, 2026. The 85,000 shares of common stock underlying the option are scheduled to vest in equal monthly installments through February 19, 2030, subject to the reporting person's continued service with the issuer.

SEC source: 0000950170-25-080887 · ownership.xml · derivative · entry 1

SCIASCIA THOMAS · CIK 0001229946 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 92,000

Underlying: Common Stock · 60,000 shares

Expires 2034-02-14

F1 · shares: Reporting person was granted a performance-based stock option on February 15, 2024, to purchase 100,000 shares of common stock. The option vested based on the attainment of established performance criteria related to the timing and successful results of the Company's Phase 2b CORAL trial of Haduvio (nalbuphine ER) in patients with chronic cough in idiopathic pulmonary fibrosis, and Phase 2 RIVER trial of Haduvio in patients with refractory chronic cough. On March 10, 2025, the Compensation Committee of the Board of Directors of the Company certified that the performance metrics related to the successful results of the RIVER trial were satisfied, resulting in the vesting of the option as to 32,000 shares of common stock. On May 31, 2025, the Compensation Committee of the Board of Directors of the Company certified that the performance metrics related to the successful results of the CORAL trial were satisfied, resulting in the vesting of the option as to 60,000 shares of common stock.

SEC source: 0000950170-25-045295 · ownership.xml · derivative · entry 3

SCIASCIA THOMAS · CIK 0001229946 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,631 shares

Expires 2025-05-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: This option was granted on May 15, 2015. The 2,631 shares of common stock underlying the option vested as to 25% of the shares on May 15, 2016 and vested as to the remaining 75% of the shares in equal monthly installments thereafter through May 15, 2019.

SEC source: 0000950170-25-045295 · ownership.xml · nonDerivative · entry 2

SCIASCIA THOMAS · CIK 0001229946 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 221,373

SEC source: 0000950170-25-045295 · ownership.xml · nonDerivative · entry 1

SCIASCIA THOMAS · CIK 0001229946 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 224,004

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 1,058 shares purchased through the Issuer's employee stock purchase plan.

SEC source: 0000950170-25-037883 · ownership.xml · derivative · entry 1

SCIASCIA THOMAS · CIK 0001229946 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,000

Underlying: Common Stock · 32,000 shares

Expires 2034-02-14

F1 · shares: Reporting person was granted a performance-based stock option on February 15, 2024, to purchase 100,000 shares of common stock. The option vests based on the attainment of established performance criteria related to the timing and successful results of the Company's Phase 2b CORAL trial of Haduvio (nalbuphine ER) in patients with chronic cough in idiopathic pulmonary fibrosis, and Phase 2 RIVER trial of Haduvio in patients with refractory chronic cough. On March 10, 2025, the Compensation Committee of the Board of Directors of the Issuer certified that the performance metrics related to the successful results of the RIVER trial were satisfied, resulting in the vesting of the option as to 32,000 shares of common stock. The performance-based stock option remains eligible for vesting with respect to additional shares of common stock underlying the option in the event that performance metrics related to the successful results of the CORAL trial are satisfied.

SEC source: 0000950170-25-024117 · ownership.xml · derivative · entry 1

SCIASCIA THOMAS · CIK 0001229946 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 116,000

Underlying: Common Stock · 116,000 shares

Expires 2035-02-17

F1 · derivative.exercise_date: This option was granted on February 18, 2025. The 116,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on February 18, 2026 and as to the remaining 75% of the shares in equal monthly installments thereafter through February 18, 2029.

SEC source: 0000950170-24-099481 · ownership.xml · derivative · entry 3

SCIASCIA THOMAS · CIK 0001229946 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 16,496 shares

Expires 2024-11-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: This option was granted on November 25, 2014. The 48,001 shares of common stock underlying the option vested as to 25% of the shares on November 25, 2015 and vested as to the remaining 75% of the shares in equal monthly installments thereafter through November 25, 2018.

SEC source: 0000950170-24-099481 · ownership.xml · nonDerivative · entry 2

SCIASCIA THOMAS · CIK 0001229946 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 220,315

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.9000 to $3.0020 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0000950170-24-099481 · ownership.xml · nonDerivative · entry 1

SCIASCIA THOMAS · CIK 0001229946 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 236,811

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000950170-24-098117 · ownership.xml · derivative · entry 9

SCIASCIA THOMAS · CIK 0001229946 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,496

Underlying: Common Stock · 18,660 shares

Expires 2024-11-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: This option was granted on November 25, 2014. The 48,001 shares of common stock underlying the option vested as to 25% of the shares on November 25, 2015 and vested as to the remaining 75% of the shares in equal monthly installments thereafter through November 25, 2018.

SEC source: 0000950170-24-098117 · ownership.xml · nonDerivative · entry 6

SCIASCIA THOMAS · CIK 0001229946 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 220,315

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.75 to $2.77 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0000950170-24-098117 · ownership.xml · nonDerivative · entry 5

SCIASCIA THOMAS · CIK 0001229946 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 238,975

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000950170-24-098117 · ownership.xml · derivative · entry 8

SCIASCIA THOMAS · CIK 0001229946 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,156

Underlying: Common Stock · 12,745 shares

Expires 2024-11-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: This option was granted on November 25, 2014. The 48,001 shares of common stock underlying the option vested as to 25% of the shares on November 25, 2015 and vested as to the remaining 75% of the shares in equal monthly installments thereafter through November 25, 2018.

SEC source: 0000950170-24-098117 · ownership.xml · nonDerivative · entry 4

SCIASCIA THOMAS · CIK 0001229946 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 220,315

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.75 to $2.8020 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0000950170-24-098117 · ownership.xml · nonDerivative · entry 3

SCIASCIA THOMAS · CIK 0001229946 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 233,060

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000950170-24-098117 · ownership.xml · derivative · entry 7

SCIASCIA THOMAS · CIK 0001229946 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,901

Underlying: Common Stock · 100 shares

Expires 2024-11-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: This option was granted on November 25, 2014. The 48,001 shares of common stock underlying the option vested as to 25% of the shares on November 25, 2015 and vested as to the remaining 75% of the shares in equal monthly installments thereafter through November 25, 2018.

SEC source: 0000950170-24-098117 · ownership.xml · nonDerivative · entry 2

SCIASCIA THOMAS · CIK 0001229946 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 220,315

SEC source: 0000950170-24-098117 · ownership.xml · nonDerivative · entry 1

SCIASCIA THOMAS · CIK 0001229946 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 220,415

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 5,882 shares purchased through the Issuer's employee stock purchase plan.

SEC source: 0000950170-24-067305 · ownership.xml · derivative · entry 3

SCIASCIA THOMAS · CIK 0001229946 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 59,354 shares

Expires 2024-07-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: This option was granted on July 2, 2014. The 59,354 shares of common stock underlying the option vested as to 25% of the shares on June 11, 2015 and vested as to the remaining 75% of the shares in equal monthly installments thereafter through June 11, 2018.

SEC source: 0000950170-24-067305 · ownership.xml · nonDerivative · entry 2

SCIASCIA THOMAS · CIK 0001229946 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 214,433

F2 · kind: This sale represents the sale of shares necessary to cover the cost of exercise and to meet tax withholding obligations as a result of the exercise of stock options on May 29, 2024.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.55 to $2.56 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

F1 · balance_after: Includes 14,723 shares purchased through the Issuer's employee stock purchase plan.

SEC source: 0000950170-24-067305 · ownership.xml · nonDerivative · entry 1

SCIASCIA THOMAS · CIK 0001229946 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 267,801

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 14,723 shares purchased through the Issuer's employee stock purchase plan.

SEC source: 0000950170-24-016460 · ownership.xml · derivative · entry 1

SCIASCIA THOMAS · CIK 0001229946 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires 2034-02-14

F1 · derivative.exercise_date: This option was granted on February 15, 2024. The 150,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on February 15, 2025 and as to the remaining 75% of the shares in equal monthly installments thereafter through February 15, 2028.

SEC source: 0001209191-23-010177 · doc4.xml · derivative · entry 1

SCIASCIA THOMAS · CIK 0001229946 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 187,500

Underlying: Common Stock · 187,500 shares

Expires 2033-02-15

F1 · derivative.exercise_date: This option was granted on February 16, 2023. The 187,500 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on February 16, 2024 and as to the remaining 75% of the shares in equal monthly installments thereafter through February 16, 2027.

SEC source: 0001209191-22-050525 · doc4.xml · derivative · entry 1

SCIASCIA THOMAS · CIK 0001229946 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,500

Underlying: Common Stock · 7,500 shares

Expires 2031-02-16

F1 · shares: Reporting person was granted a performance-based stock option on February 17, 2021, to purchase 37,500 shares of common stock. The option vests based on the attainment of established performance criteria related to the timing and successful results of the Company's Phase 2b/3 PRISM trial of Haduvio (nalbuphine ER) for the treatment of prurigo nodularis, and Phase 2 CANAL trial of Haduvio for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis. On September 19, 2022, the Compensation Committee of the Board of Directors of the Issuer certified that the performance metrics related to the successful results of the CANAL trial were satisfied, resulting in the vesting of the option as to the 7,500 shares of common stock.

SEC source: 0001209191-22-040290 · doc4.xml · derivative · entry 1

SCIASCIA THOMAS · CIK 0001229946 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2031-02-16

F1 · shares: Reporting person was granted a performance-based stock option on February 17, 2021, to purchase 37,500 shares of common stock. The option vests based on the attainment of established performance criteria related to the timing and successful results of the Company's Phase 2b/3 PRISM trial of Haduvio (nalbuphine ER) for the treatment of prurigo nodularis, and Phase 2 CANAL trial of Haduvio for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis. On June 29, 2022, the Compensation Committee of the Board of Directors of the Issuer certified that certain performance metrics related to the successful results of the PRISM trial were satisfied, resulting in the vesting of the option as to 30,000 shares of common stock. The performance-based option remains eligible for vesting with respect to the remaining shares of common stock underlying the option in the event that additional performance metrics related to the successful results of the CANAL trial are satisfied.

SEC source: 0001209191-22-009743 · doc4.xml · derivative · entry 1

SCIASCIA THOMAS · CIK 0001229946 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 110,000

Underlying: Common Stock · 110,000 shares

Expires 2032-02-10

F1 · derivative.exercise_date: This option was granted on February 11, 2022. The 110,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on February 11, 2023 and as to the remaining 75% of the shares in equal monthly installments thereafter through February 11, 2026.

SEC source: 0001209191-22-040277 · doc4a.xml · derivative · entry 1

SCIASCIA THOMAS · CIK 0001229946 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 110,000

Underlying: Common Stock · 110,000 shares

Expires 2032-02-10

F1 · derivative.exercise_date: This option was granted on February 11, 2022. The 110,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on February 11, 2023 and as to the remaining 75% of the shares in equal monthly installments thereafter through February 11, 2026.

F2 · ownership.direct: This amendment to the Form 4 originally filed for the reporting person on February 15, 2022 is being filed solely to attach the power of attorney exhibit that was inadvertently excluded from the original filing.

SEC source: 0000899243-21-007377 · doc4.xml · derivative · entry 1

SCIASCIA THOMAS · CIK 0001229946 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2031-02-16

F1 · derivative.exercise_date: This option was granted on February 17, 2021. The 50,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on February 17, 2022 and as to the remaining 75% of the shares in equal monthly installments thereafter through February 17, 2025.

SEC source: 0000899243-20-004877 · doc4.xml · derivative · entry 1

SCIASCIA THOMAS · CIK 0001229946 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2030-02-12

F1 · derivative.exercise_date: This option was granted on February 13, 2020. The 60,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on February 13, 2021 and as to the remaining 75% of the shares in equal monthly installments thereafter through February 13, 2024.

SEC source: 0000899243-19-015606 · doc4.xml · derivative · entry 1

SCIASCIA THOMAS · CIK 0001229946 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2029-06-02

F1 · derivative.exercise_date: This option was granted on June 3, 2019. The 50,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on June 3, 2020 and as to the remaining 75% of the shares in equal monthly installments thereafter through June 3, 2023.

SEC source: 0000899243-19-013248 · doc4.xml · derivative · entry 3

SCIASCIA THOMAS · CIK 0001229946 · Chief Medical Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,565 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F2 · derivative.exercise_date: On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F2 · derivative.expiration_date: On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

SEC source: 0000899243-19-013248 · doc4.xml · derivative · entry 2

SCIASCIA THOMAS · CIK 0001229946 · Chief Medical Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 15,553 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On May 9, 2019, the Series A Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F1 · derivative.exercise_date: On May 9, 2019, the Series A Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F1 · derivative.expiration_date: On May 9, 2019, the Series A Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

SEC source: 0000899243-19-013248 · doc4.xml · nonDerivative · entry 1

SCIASCIA THOMAS · CIK 0001229946 · Chief Medical Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 193,724

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: On May 9, 2019, the Series A Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F2 · price: On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.